Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methiodal
- Development stage
- Unknown
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intrathecal
01
Overview
Methiodal is a small molecule pharmaceutical drug that was used as an iodinated contrast medium for X-ray imaging procedures such as myelography (imaging of the spinal cord). It belongs to the class of organosulfonic acids and acts as a radiopaque agent by absorbing X-rays due to its iodine content. Methiodal has been associated with cases of adhesive arachnoiditis when used in myelography. It is no longer marketed anywhere in the world as of 2021[1][2][3][4][5].
- Brand names
- AbrodilConturexKontrast U
- Other names
- methiodaliodomethanesulfonic acidmethiodal sodium
Beyond the preview
Go deeper on methiodal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methiodal.